FH535

FH535 is an inhibitor of Wnt/β-catenin and PPAR with anti-tumor activities[1].

Product Specifications

CAS Number

[108409-83-2]

UNSPSC

12352005

Hazard Statement

H302, H318

Target

PPAR; Wnt; β-catenin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fh535.html

Purity

99.95

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=S(C1=CC(Cl)=CC=C1Cl)(NC2=CC=C([N+]([O-])=O)C=C2C)=O

Molecular Formula

C13H10Cl2N2O4S

Molecular Weight

361.20

Precautions

H302, H318

References & Citations

[1]Handeli S, et al. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008 Mar;7 (3) :521-9.|[2]Wu MY, et al. FH535 inhibited metastasis and growth of pancreatic cancer cells. Onco Targets Ther. 2015 Jul 6;8:1651-70.|[3]Liu L, et al. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget. 2016 Jul 26;7 (30) :47145-47162.